Previous Article | Next Article ![]()
Journal of Virology, July 1999, p. 5698-5706, Vol. 73, No. 7
Génétique des Virus (ICGM-CNRS
UPR0415),
Received 28 October 1998/Accepted 16 March 1999
Lentiviruses have in their transmembrane glycoprotein (TM) a highly
immunogenic structure referred to as the principal immunodominant domain (PID). The PID forms a loop of 5 to 7 amino acids between two conserved cysteines. Previous studies showed that envelope (Env) glycoprotein functions of feline immunodeficiency virus (FIV)
could be retained after extensive mutation of the PID loop sequence, in
spite of its high conservation. In order to compare Env
function in different lentiviruses, either random mutations were
introduced in the PID loop sequence of human immunodeficiency virus
type 1 (HIV-1) or the entire HIV-1 PID loop was replaced by the
corresponding PID loop of FIV or simian immunodeficiency virus (SIV).
In the macrophage-tropic HIV-1 ADA Env, mutations impaired the
processing of the gp160 Env precursor, thereby abolishing viral
infectivity. However, 6 of the 108 random Env mutants that were
screened retained the capacity to induce cell membrane fusion. The SIV
and FIV sequences and five random mutations were then introduced in the
context of T-cell-line-adapted HIV-1 LAI which, although phenotypically
distant from HIV-1 ADA, has an identical PID loop sequence. In contrast
to the situation for HIV-1 ADA mutants, the cleavage of the Env
precursor was unaffected in most HIV-1 LAI mutants. Such mutations,
however, resulted in increased shedding of the gp120 surface
glycoprotein (SU) from the gp41 TM. The HIV-1 LAI Env mutants showed
high fusogenic efficiency. Three Env mutants retained the capacity to
mediate virus entry in target cells, although less efficiently than the
wild-type Env, and allowed the reconstitution of infectious molecular
clones. These results indicated that in HIV-1, like FIV, the
conserved PID sequence can be changed without impairing Env function.
However, functional constraints on the PID of HIV-1 vary depending
on the structural context of Env, presumably in relation to the
role of the PID in the interaction of the SU and TM subunits and the stability of the Env complex.
The envelopes (Env) of lentiviruses,
despite wide sequence divergence, share certain structural features
(14, 15, 30). In particular, the transmembrane glycoprotein
(TM) of lentiviruses has a Cys(X)5-7Cys motif which
appears to be folded as a loop between two cysteines linked by a
disulfide bond (14, 27). Remarkably, this domain elicits a
strong antibody response in all lentiviral infections and constitutes
the principal immunodominant domain (PID) of the TM of lentiviruses
(3, 8, 16, 26, 29, 52). The PID, located in the middle of
the TM ectodomain, forms a hinge between two In spite of these peculiar structural and immunological
characteristics, the functional relevance of the PID remains unclear. The presence of the loop structure appears to be essential, because disruption of the cysteine loop affected Env processing both in human
immunodeficiency virus type 1 (HIV-1) and in feline immunodeficiency virus (FIV) (10, 28, 46). Nevertheless, extensive changes, including mutation of four of the six highly conserved residues located
between the cysteines, could be introduced in the FIV PID without
disrupting Env functions, such as the capacities to induce syncytia and
to mediate infection in cell cultures. Conversely, these mutations
modified the antigenic properties of the FIV PID (32; unpublished observations).
The functional tolerance of PID changes in FIV was surprising,
considering the extreme phylogenetic conservation of this domain. In
order to verify whether our observations for FIV held true for other
lentiviruses, we wished to analyze PID functions in HIV-1. Indeed,
HIV-1 is of special interest in this regard. First, the PID sequence is
highly conserved among different HIV-1 isolates despite structural and
functional differences in the Env of macrophage-tropic (M-tropic; now
called R5) and T-cell-line-tropic (T-tropic; now called X4) isolates
(2, 42, 48). Thus, the influence of the PID on Env functions
in different contexts may be addressed. Second, antibodies directed
against the PID of HIV-1 enhance in vitro infection (5, 13, 34,
35). It may therefore be of interest to modify the immunological
properties of the PID to diminish the potential enhancing response for
vaccine purposes.
In this study, we performed extensive mutagenesis of the PID of HIV-1
in the context of two different HIV-1 isolates, the M-tropic isolate
HIV-1 ADA and the T-cell-line-adapted (TCLA) isolate HIV-1 LAI. The
functional consequences of the mutations were analyzed with regard to
Env expression and processing, syncytium-forming ability, and
infectivity. Although the PID is identical in the isolates studied, we
observed that identical mutations have different consequences in the
two different Env backgrounds.
Plasmids.
The env expression vector pSV7d,
containing the HIV-1 ADA envelope, and the
pNL-Luc-E Cell cultures.
COS, 293T, and HeLa cells were cultured in
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10%
fetal calf serum (FCS). The HeLa P4 cell line, which stably expresses
the CD4 receptor and contains an integrated Tat-inducible LacZ gene,
and the HeLa P5 cell line, which is derived from HeLa P4 and expresses
the chemokine receptor CCR5 (33), were kindly provided by M. Alizon. The MT4 cell line was cultured in RPMI 1640 supplemented with 10% FCS.
PID mutagenesis. (i) Random mutagenesis of the PID of ADA
Env.
An EagI site was introduced into ADA
env (positions 1808 to 1813) contained in plasmid pSV7d-ADA,
without changing the encoded amino acids, by use of the ExSite
PCR-based site-directed mutagenesis kit (Stratagene) according to the
manufacturers' instructions. The oligonucleotides
5'-GGTGCAGATGAGTTTTCCAGAGCAACCCCAAAT-3' and 5'-ACGGCCGTGCCTTGGAATGCTAGTTGGAGTAATA-3' (containing the
EagI site and 5' phosphorylated) were used as mutagenesis
primers. The plasmid obtained, pSV7d-ADA-E, was used to clone DNA
fragments containing PID mutations (see below) between the
AvrII (positions 1767 to 1772) and EagI sites.
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Variable Constraints on the Principal
Immunodominant Domain of the Transmembrane Glycoprotein of Human
Immunodeficiency Virus Type 1

![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-helical domains which
are thought to be involved in the transition of the Env complex from
the native to the fusogenic state (6, 47). The conservation
of this structure suggests that it has an essential function in the
viral life cycle. On the basis of immunological and computer modeling data, it has been suggested that the PID comes in contact with the C
terminus of the surface glycoprotein (SU) and participates in the
noncovalent association of the SU and TM subunits of the Env oligomeric
complex (22, 39, 40).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
R+ vector, containing the
env-deleted HIV-1 provirus into which the luc
gene has been introduced (9), were kindly provided by T. Dragic and E. Landau (Aaron Diamond AIDS Research Center, New York,
N.Y.). The HIV-1 LAI env expression vector (pMA243/105 vector) (41) and the LAI provirus molecular clone (90.1)
(1) were gifts from M. Alizon (Institut Cochin de
Génétique Moléculaire, Paris, France). The
rev expression vector pcREV (23) was provided by
B. Shacklett (Aaron Diamond AIDS Research Center).
(ii) Construction of chimeric PIDs of ADA Env. The AvrII and EagI sites were also used to generate PID mutants in which the sequences between the cysteines were replaced with the corresponding sequences of FIV env and simian immunodeficiency virus (SIV) env (these mutants were designated FivA and SivA). For this purpose, two sets of oligonucleotides (also containing the NdeI site) were hybridized with each other to generate double-stranded DNA fragments that were cloned into pSV7d-ADA-E. The oligonucleotides were 5'-CTAGGCATATGGGGTTGCAATCAAAATCAATTCTTCTGCACCAC-3' and 5'-GGCCGTGGTGCAGAAGAATTGATTTTGATTGCAACCCCATATGC-3' for the FIV PID and 5'-CTAGGCATATGGGGTTGCGCGTTTAGACAAGTCTGCACCAC-3' and 5'-GGCCGTGGTGCAGACTTGTCTAAACGCGCAACCCCATATGC-3' for the SIV PID. Minipreparations of plasmids (minipreps) were prepared by use of the Wizard Minipreps DNA purification system. Recombinant clones were identified by NdeI digestion and used to transfect COS cells.
(iii) Site-directed mutagenesis of LAI env. The PID sequences of four fusogenic mutants of ADA Env (p34A, t7A, t24A, and t25A) and of three nonfusogenic mutants (t35A and the chimeric PIDs containing the FIV and SIV PID sequences [see Table 2]) were introduced into LAI env by site-directed mutagenesis by an adaptation of the method described by Kunkel (20). For this purpose, the SmaI-BamHI fragment (positions 6818 to 8068) of pMA243/105 that contains a 1,950-bp fragment of LAI env (positions 6818 to 8068) was introduced into pTZ18 and used as a target for oligonucleotide-directed mutagenesis. The EagI site was introduced into the mutagenesis oligonucleotides (positions 7600 to 7650), without changing the encoded amino acids, in order to enable the selection of mutant clones. The NheI-BamHI fragments (positions 6853 to 8068) containing the mutations were then introduced into expression vector pMA243/105. These LAI env mutants were designated FivL, SivL, t35L, p34L, t7L, t24L, and t25L.
(iv) Sequencing. The LAI and ADA Env mutants were entirely sequenced to confirm the mutations introduced into the PIDs and to ensure that no other changes were introduced elsewhere during mutagenesis.
Construction of infectious molecular clones. The LAI Env mutants that were shown to maintain high fusogenicity (p34L, t7L, t24L, and t25L) and the FIV and SIV sequences were introduced into the LAI infectious molecular clone (90.1) by use of SalI and BamHI sites (positions 5367 and 8068, respectively).
Cell transfection. Transfection was performed by the calcium phosphate precipitation method (36). COS, 293T, or HeLa cells were plated either at 250,000 cells per well in a six-well plate or at 1.2 × 106 cells per 10-cm-diameter petri dish on the day before transfection. Under these conditions, cells were confluent on day 3 after transfection.
Detection and quantitation of Env glycoproteins by an
enzyme-linked immunosorbent assay (ELISA).
For the screening
procedure and to detect potentially functional ADA Env mutants, samples
were prepared as follows. COS cells plated in six-well dishes were
transfected with 500 ng of both env expression vectors and
the pNL-Luc-E
R+ vector. On the following day,
the culture medium was changed; 48 h later, supernatants were
harvested, centrifuged for 10 min at 2,000 × g,
treated with Empigen BB (0.25% final concentration) (Calbiochem), and
centrifuged again for 30 min at 13,000 × g. Cells were
washed with cold phosphate-buffered saline (PBS), lysed with 0.5%
Empigen BB in 0.5 ml of PBS, and centrifuged for 10 min at
1,500 × g and for 1 h at 13,000 × g. Sample dilutions were made in DMEM-10% FCS, maintaining the
final concentration of Empigen BB at 0.25%.
Fusion assays.
The fusion assay for the ADA mutants
consisted of cotransfecting in triplicate the mutated env
expression vectors and pNL-Luc-E
R+, which
expresses in trans the Rev and Tat proteins, into the 293T
cell line (2 µg of each plasmid per well) and coculturing the
transfected cells with an equal number (250,000 cells per well) of HeLa
P5 cells. Env-induced syncytia were detected by an in situ
-galactosidase assay as described previously (11). For
the LAI mutants, 293T cells were transfected with 3 µg of DNA from
env expression vectors derived from pMA243/105, which contains the tat and rev genes, per well. Cells
were then cocultured with the HeLa P4 or P5 cell line, and syncytia
were visualized as described above.
RIPA. Either 293T cells or HeLa P4 or P5 cells plated on 10-cm petri dishes were transfected with 10 µg of env expression vector. In the case of the ADA constructions, 5 µg of pcREV was cotransfected. At 36 h after transfection, cells were harvested in methionine-cysteine-deprived medium (ICN) for 1 h and then labelled overnight with 100 µCi of Pro-mix L-35S-labelling mix (Amersham) per ml. The supernatants (4 ml/dish) were centrifuged for 10 min at 1,500 × g, mixed with 400 µl of 10× radioimmunoprecipitation assay (RIPA) buffer (RB) (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM KCl, 1% Triton X-100, 0.5% sodium deoxycholate, 1 mM Pefabloc [Boehringer Mannheim Biochemicals], 5 µg of aprotinin [Boehringer] per ml, 5 µg of leupeptin [Boehringer] per ml), and centrifuged again at 3,000 × g for 1 h. Cells were lysed in RB, and nuclei and cell fragments were eliminated by centrifugation (10 min at 1,200 × g and 1 h at 17,000 × g). Cell lysates and supernatants were then incubated overnight with 50 µl of protein G-agarose suspension in RB. After centrifugation, all samples were incubated for 3 h with D7323 and D7324 antibodies, both at a final concentration of 10 µg/ml, and overnight with 50 µl of protein G-agarose. After centrifugation, pellets were washed twice with RB, twice with a high-salt buffer (50 mM Tris-HCl [pH 7.5], 500 mM NaCl, 0.1% Triton X-100, 0.05% sodium deoxycholate), and once with a low-salt buffer (50 mM Tris-HCl [pH 7.5], 0.1% Triton X-100, 0.05% sodium deoxycholate). Immunoprecipitates were eluted by boiling protein G beads in 50 µl of Laemmli buffer (18). All steps before elution were performed at 4°C. Immunoprecipitates were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis on a 10% gel. For quantification of Env glycoproteins, gels were dried and exposed on a Molecular Dynamics Storage Fluor screen. Band radioactivity was measured with a PhosphorImager SI and ImageQuant software.
Virus entry complementation assay.
293T cells were plated at
1.2 × 106 cells per 10-cm-diameter petri dish on the
day before transfection. Wild-type and mutant env expression
vectors were cotransfected with pNL-Luc-E
R+
(7.5 µg of each) to generate Env-pseudotyped virions. Supernatants were collected after 48 h, and p24gag levels were
measured with a commercial ELISA kit (Innogenetics, Zwijndrecht,
Belgium). Supernatants of cells transfected only with
pNL-Luc-E
R+ were used as controls. Target
cells plated in either 24-well dishes for HeLa P4 or HeLa P5 cells
(105 cells per well) and MT4 cells (106 cells
per well) or 48-well dishes for MDM were incubated overnight in
triplicate with 1 ml of viral supernatant containing 100 ng of p24.
Cells were lysed for either 2 days (HeLa P4, HeLa P5, and MT4) or 3 days (MDM) after infection with 100 µl of luciferase lysis buffer
(Promega Corp., Madison, Wis.). The amount of luciferase activity in 20 µl of lysate was measured by use of commercially available reagents
(Promega) in a luminometer.
Infectivity assay. Viral supernatants were obtained by transfecting 293T cells (plated as indicated above) with 15 µg of DNA from LAI wild-type and mutant proviruses. Medium was replaced at 6 and 24 h after transfection. Supernatants were collected 24 h later, and the concentration of p24 was measured by an ELISA. Cells (MT4 cells plated at 2 × 105 cells per well in 96-well dishes or HeLa P4 cells plated at 2 × 105 cells per well in 6-well dishes) were infected for 3 h with viral supernatant containing 100 ng of p24 per ml and then washed with PBS to eliminate the input p24. HeLa P4 cells were split every 3 days. Kinetics of infection were monitored in triplicate by measurement of p24 contained in the culture supernatants.
| |
RESULTS |
|---|
|
|
|---|
Selection of random mutants of the ADA Env PID.
In order to
select recombinant clones producing Env and thus to discard
nonfunctional constructions (i.e., containing stop codons or
frameshifts), clones derived from random mutagenesis were screened by
detection of Env products in cell lysates and supernatants of COS cells
after transfection with the DNA recovered from minipreps corresponding
to single colonies. To achieve Env expression, Rev was produced in
trans by cotransfecting
pNL-Luc-E
R+. A total of 108 clones derived
from mutagenesis of the env expression vector pSV7d-ADA were
analyzed. Seventy-two clones were obtained by random mutagenesis of all
five codons of the cysteine loop of the PID, and 36 clones were
obtained by random mutagenesis of the three N-terminal codons of the
cysteine loop. At 72 h after transfection, the presence of Env
glycoproteins in cell extracts and supernatants was tested by an ELISA
with both anti-SU (D7324) and anti-TM (D7323) antibodies. Env products
were detected in cell lysates from most transfections (86 of 108). For
24 clones, Env reactivity was also found in supernatants, suggesting
Env processing and gp120 production. The 32 clones (19 p clones and 13 t clones) showing the highest Env production in cell lysates were selected for further analysis.
Capacity of HIV-1 ADA Env mutants for fusion and complementation of
virus entry.
The two chimeric ADA Env mutants in which the
sequence of the HIV-1 PID loop was replaced by the corresponding
sequences of FIV and SIV (FivA and SivA) and the 32 clones selected
following random mutagenesis were analyzed by a syncytial assay for
their ability to induce cell membrane fusion. Env mutants were
cotransfected with the pNL-Luc-E
R+ vector
into 293T cells. HeLa P5 target cells were then added, permitting the
detection of fusion events by in situ
-galactosidase staining. Six
mutant clones were capable of inducing cell fusion, although with less
efficiency than the wild-type envelope. Table 1 shows the results of a representative
syncytium-forming assay. The 28 other mutant clones, including FivA and
SivA, did not induce cell fusion. The sequences of the fusogenic
mutants are shown in Table 2; for
comparison, the sequences of the PIDs of some nonfusogenic clones are
also presented. All of the fusogenic clones contained mutations in the
three N-terminal residues, while none bore mutations in the two
C-terminal residues, although mutations in these positions were present
in several clones tested (Table 2). No other mutation outside the PID
was found by sequencing of the Env mutants.
|
|
Capacity of HIV-1 LAI Env mutants for fusion and complementation of virus entry. Some of the mutations analyzed in the context of HIV-1 ADA Env were introduced into Env of the TCLA isolate HIV-1 LAI in order to determine whether the effect of PID changes was the same in a different Env background. The selected PID mutations represented four (of six) fusogenic (p34A, t7A, t24A, and t25A) and three nonfusogenic (t35A, FivA, and SivA) ADA Env mutants (Table 2).
The fusogenic properties of the HIV-1 LAI Env mutants were analyzed after transfection of 293T cells and coculturing with the HeLa P5 cell line. The number of syncytia and the number of nuclei in the syncytia are presented in Table 3. In contrast to their ADA counterparts, four LAI Env mutants (p34L, t7L, t24L, and t25L) showed a syncytium-forming capacity similar to that of the wild-type LAI Env. Three other LAI Env mutants (t35L, FivL, and SivL), containing mutations which abolished fusogenic capacity in the context of ADA Env, were able to form syncytia. Similar results were obtained when HeLa P4 cells were used as target cells (data not shown). The capacity of the HIV-1 LAI Env mutants to mediate the transduction of pseudotyped viral particles was assessed with either HeLa P4 or MT4 cell lines. As Fig. 1 shows, luciferase activity was detected in both target cell lines with mutants t7L, t24L, and t25L but not with mutants p34L, t35L, FivL, and SivL. However, the signal obtained with viral particles pseudotyped with the Env mutants was reduced by approximately 1 log unit in both MT4 (Fig. 1A) and HeLa P4 (Fig. 1B) cells compared to the signal obtained with wild-type Env.
|
|
Infectivity of LAI mutant viruses. To analyze the infectious properties of the LAI Env mutants in greater detail, the p34L, t7L, t24L, t25L, FivL, and SivL mutations were introduced into the HIV-1 LAI infectious molecular clone, yielding the P34L, T7L, T24L, T25L, FIVL, and SIVL mutant viruses. The kinetics of replication of the mutant viruses were monitored with the MT4 cell line. Supernatants containing equal amounts of p24 were used for infections. As shown in Fig. 2, the T7L, T24L, and T25L mutant viruses were able to establish a productive infection. The level of replication of the infectious mutant viruses, as evaluated by measurement of p24 in supernatants, appeared to be inferior by approximately 1 log unit to that of the wild-type virus. This difference was similar to that observed in entry assays. This decrease in the infectivity of the mutant viruses in relation to the wild-type virus was confirmed when the experiment was performed with HeLa P4 cells (data not shown).
|
Influence of PID mutations on Env processing and stability. To analyze the expression and processing of the mutant Env glycoproteins, 293T cells were transfected either with HIV-1 ADA wild-type Env and four mutants (p34A, t7A, t24A, and t25A) or with HIV-1 LAI wild-type Env and the four corresponding mutants (p34L, t7L, t24L, and t25L). After 48 h, Env products were analyzed by a RIPA with two sheep antibodies, anti-HIV-1 gp120 (D7324) and anti-HIV-1 gp41 (D7323). Figure 3A shows the results of a RIPA performed on lysates of cells transfected with ADA Env mutants. Although the mutant Env precursors (Pr) were produced at levels comparable to those of wild-type Env, SU gp120 was not detectable for any of the mutants. The impaired processing of the ADA mutants contrasted with the efficient cleavage of the Pr into SU and TM subunits that was observed for the four LAI mutants (Fig. 3B).
|
|
|
|
|
| |
DISCUSSION |
|---|
|
|
|---|
We have previously shown that the PID loop of FIV, despite its conservation in natural isolates, can be modified without impairing Env function and viral infectivity (32). In this study, we have examined the effect of mutations in the PID loop on the functional properties of HIV-1 Env in an attempt to define the structural constraints that could account for the high level of conservation of this domain in lentiviruses. PID mutations were introduced in the Env from an M-tropic HIV-1 isolate and a TCLA isolate of HIV-1 to analyze the role of the PID in different structural backgrounds. Our results revealed that, although HIV-1 Env can tolerate extensive changes in the PID, functional permissivity varies between different isolates.
Changes in the PID in the context of ADA Env resulted in a loss of the capacity to mediate virus entry into target cells. Some mutants, however, partially retained fusogenic ability. When introduced into HIV-1 LAI, identical mutations neither impaired syncytium-forming ability nor abolished the capacity of the virus to infect cells. Indeed, infectious LAI mutant viruses containing up to three nonconservative changes in the sequence contained between the cysteines were obtained. Moreover, Env chimeras with unrelated sequences from the PIDs of other lentiviruses (FIV and SIV) exhibited fusogenic capacity.
Biochemical analysis of the expression and maturation of the Env mutants revealed that PID mutations affected the intracellular processing of HIV-1 ADA Env by reducing the cleavage of gp160 Env Pr, while the same mutations had no appreciable effect on HIV-1 LAI Env Pr cleavage. These data strongly suggest that the defects in syncytium-forming ability and infectivity observed in ADA mutants are a direct consequence of the decreased efficiency of Env Pr processing.
Measurements of the release of SU gp120 in cell supernatants and of the association index for the LAI Env mutants revealed that PID mutations caused destabilization of the Env complex and a consequent increase in SU shedding. An increase in gp120 shedding was also indicated by the reduction of gp120 associated with mutant virions. This finding may be the major cause of the diminished infectivity of the LAI mutants. Accordingly, the p34L mutant, exhibiting the lowest level of virion-associated gp120 (Fig. 6A), was not infectious.
These results support the hypothesis that the PID loop is involved in the association between the SU and TM subunits (40). Even a single change in the PID, from a basic to an acidic residue (K to E in the t25L mutant), was sufficient to cause an augmentation of SU shedding. Other mutations in TM outside the PID loop have also been shown to affect the SU-TM association (4, 7), suggesting either that several points of contact exist between the two glycoproteins or that these mutations cause structural modifications which reduce the fitness of the subunit interaction.
If the reduction in the SU-TM association upon mutation of the PID is expected considering the putative position of the PID at the interface of the two subunits, it is surprising that the same mutations have such different effects on the processing of gp160 of ADA and LAI. Compared to that of M-tropic isolates, including HIV-1 ADA, the SU of TCLA isolates is more prone to be shed from the TM (38, 39, 43, 44, 50). The intracellular conformation of Pr may reflect properties of the spatial structure assumed later by the SU and TM subunits at the cell and virion surfaces. Like the CD4 binding properties of the SU, which are already present in Env Pr (12), the instability of the SU-TM interaction in the mature Env complex of TCLA isolates might already be determined in the Pr structure. For LAI Env, the early steps of folding could leave a loose contact between the N- and C-terminal portions of Env Pr, destined to become the SU and TM subunits, thus permitting modification of the PID without alteration of its transport and cleavage. In contrast, in the ADA context, the PID would be involved in a closer interaction with the N-terminal half of the Pr such that mutation of the PID would diminish the probability of correct folding of the Pr. Increased retention of misfolded Pr molecules in the rough endoplasmic reticulum would follow, thus preventing the endoproteolytic cleavage in SU and TM which occurs in the Golgi complex (45, 49).
Adaptation of HIV-1 to replicate in T-cell lines, as well as changes in tropism, has been related to amino acid substitutions in the SU (17, 19, 42, 48, 51). Such mutations mainly affect gp120 binding and interaction with cell membrane receptors. Our results suggest that adaptation to T-cell cultures is also concurrent with a decrease in structural constraints on the PID. SU-TM interactions are critical in the postbinding rearrangements of the Env that initiate the fusion process. Indeed, an early step in the conformational changes triggered by Env binding to soluble CD4 in TCLA isolates involves the dissociation of the SU from the TM, with exposure of cryptic epitopes of the TM, including epitopes located in the PID (25, 37). Weaker structural constraints on the PID of HIV-1 LAI than on the PID of HIV-1 ADA could be related to diversity in the nature of the conformational changes occurring during entry in different cell types. While further studies with additional isolates of HIV-1 are needed to address this hypothesis, the HIV-1 LAI PID mutants that showed a reduced SU-TM association without a disruption of fusion capacity and infectivity will be useful for analyzing the relationship between Env stability and conformational changes in greater detail.
We have previously proposed that, given the observed tolerance for mutations in the PID, the conservation of its sequence might be due in part to selective pressure for the conservation of epitopes eliciting enhancing antibodies (32). Several anti-PID antibodies obtained from HIV-1-infected patients enhance cell culture infection by either T- or M-tropic viruses (5, 13, 34, 35), and anti-PID reactivity has been correlated with the probability of mother-to-child transmission of HIV-1 infection (21, 31). In this study, we did not analyze the immunological properties of the mutated PID. Should mutations modify the immunogenicity of the PID of HIV-1, as was the case for FIV mutants of PID (32), the use as immunogens of HIV-1 Env mutants with mutations in the PID, as presented here, to avoid the induction of potentially enhancing anti-PID antibodies while maintaining a functional conformation able to induce neutralizing antibodies could be advantageous for AIDS vaccine development.
| |
ACKNOWLEDGMENTS |
|---|
We thank E. Gomas and F. Letourneur for performing DNA sequencing. We are grateful to T. Dragic, E. Landau, M. Alizon, and B. Shacklett for providing HIV-1 vectors and cells and to M. Girard and the Agence Nationale de Recherche sur le SIDA for rgp120. We are indebted to M. Alizon and J. Richardson for helpful discussion and critical reading of the manuscript and to D. Strosberg for continuous support.
This work was supported by the Agence Nationale de Recherche sur le SIDA and a Biomed 2 grant from the European Economic Community. R.M. was supported by grants from la Fondation pour la Recherche Médicale/SIDAction-Ensemble Contre le SIDA, Paris, France.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Institut Cochin de Génétique Moléculaire, Génétique des Virus, 22 rue Méchain, 75014 Paris, France. Phone: (33)-01 40 51 64 15. Fax: (33)-01 40 51 72 10. E-mail: sonigo{at}cochin.inserm.fr.
Present address: Policlinique de Dermatologie, Hôpital
Saint-Louis, 75010 Paris, France.
Present address: Laboratoire de Biologie des Rétrovirus,
Institut Pasteur, 75724 Paris Cedex 15, France.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Adachi, A.,
H. E. Gendelman,
S. Koenig,
T. Folks,
R. Willey,
A. Rabson, and M. A. Martin.
1986.
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.
J. Virol.
59:284-291 |
| 2. | Berger, E. A., R. W. Doms, E.-M. Fenyö, B. T. M. Korber, D. R. Littman, J. P. Moore, Q. J. Sattentau, H. Schuitemaker, J. Sodroski, and R. A. Weiss. 1998. A new classification for HIV-1. Nature 391:240[Medline]. |
| 3. |
Bertoni, G.,
M.-L. Zahno,
R. Zanoni,
H.-R. Vogt,
E. Peterhans,
G. Ruff,
W. P. Cheevers,
P. Sonigo, and G. Pancino.
1994.
Antibody reactivity to the immunodominant epitopes of the caprine arthritis-encephalitis virus gp38 transmembrane glycoprotein associates with the development of arthritis.
J. Virol.
68:7139-7147 |
| 4. |
Cao, J.,
L. Bergeron,
E. Helseth,
M. Thali,
H. Repke, and J. Sodroski.
1993.
Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein.
J. Virol.
67:2747-2755 |
| 5. | Cavacini, L. A., C. L. Emes, A. V. Wisnewski, J. Power, G. Lewis, D. Montefiori, and M. R. Posner. 1998. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res. Hum. Retroviruses 14:1271-1280[Medline]. |
| 6. | Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273[Medline]. |
| 7. |
Chen, S. S.-L.
1994.
Functional role of the zipper motif region of human immunodeficiency virus type 1 transmembrane protein gp41.
J. Virol.
68:2002-2010 |
| 8. |
Chong, Y.-H.,
J. M. Ball,
C. J. Issel,
R. C. Montelaro, and K. E. Rushlow.
1991.
Analysis of equine humoral responses to the transmembrane envelope glycoprotein (gp45) of equine infectious anemia virus.
J. Virol.
65:1013-1018 |
| 9. | Connor, R. I., K. C. Benjamin, S. Choe, and N. R. Landau. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944[Medline]. |
| 10. |
Dedera, D.,
R. Gu, and L. Ratner.
1992.
Conserved cysteine residues in the human immunodeficiency virus type 1 transmembrane envelope protein are essential for precursor envelope cleavage.
J. Virol.
66:1207-1209 |
| 11. |
Dragic, T., and M. Alizon.
1993.
Different requirements for membrane fusion mediated by the envelopes of human immunodeficiency virus types 1 and 2.
J. Virol.
67:2355-2359 |
| 12. |
Earl, P. L.,
B. Moss, and R. W. Doms.
1991.
Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope proteins.
J. Virol.
65:2047-2055 |
| 13. | Eaton, A. M., K. E. Ugen, D. B. Weiner, T. Wildes, and J. A. Levy. 1994. An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement. AIDS Res. Hum. Retroviruses 10:13-18[Medline]. |
| 14. | Gallaher, W. R., J. M. Ball, R. F. Barry, M. C. Griffin, and R. C. Montelaro. 1989. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses 5:431-440[Medline]. |
| 15. | Gallaher, W. R., J. M. Ball, R. F. Garry, A. M. Martin-Amedee, and R. C. Montelaro. 1995. A general model for the surface glycoproteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses 11:191-202[Medline]. |
| 16. |
Gnann, J. W., Jr.,
J. A. Nelson, and M. B. A. Oldstone.
1987.
Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus.
J. Virol.
61:2639-2641 |
| 17. |
Groenink, M.,
R. Fouchier,
S. Broersen,
C. Baker,
M. Koot,
A. van't Wout,
J. G. Huisman,
F. Miedema,
M. Tersmette, and H. Schuitemaker.
1993.
Relation of phenotype evolution of HIV-1 to envelope V2 configuration.
Science
260:1513-1516 |
| 18. | Harlow, E., and D. Lane. 1988. Antibodies, a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 19. |
Hwang, S. S.,
T. J. Boyle,
H. K. Lyerly, and B. R. Cullen.
1991.
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.
Science
253:71-73 |
| 20. |
Kunkel, T. A.
1985.
Rapid and efficient site-specific mutagenesis without phenotypic selection.
Proc. Natl. Acad. Sci. USA
82:488-492 |
| 21. | Lallemant, M., A. Baillou, S. Lallemant-Le Coeur, S. Nzingoula, M. Mampaka, P. M'Pelé, F. Barin, and M. Essex. 1994. Maternal antibody response at delivery and perinatal transmission of human immunodeficiency virus type 1 in African women. Lancet 343:1001-1005[Medline]. |
| 22. | Lopalco, L., R. Longhi, F. Ciccomascolo, A. De Rossi, M. Pelagi, F. Andronico, J. P. Moore, T. Schultz, A. Beretta, and A. G. Siccardi. 1993. Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies. AIDS Res. Hum. Retroviruses 9:33-39[Medline]. |
| 23. | Malim, M. H., J. Hauber, R. Fenrick, and B. R. Cullen. 1988. Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature 335:181-183[Medline]. |
| 24. | Moore, J. M., and R. F. Jarret. 1988. Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1. AIDS Res. Hum. Retroviruses 4:369-379[Medline]. |
| 25. |
Moore, J. P.,
J. A. McKeating,
R. A. Weiss, and Q. J. Sattentau.
1990.
Dissociation of gp120 from HIV-1 virions induced by soluble CD4.
Science
250:1139-1142 |
| 26. | Norrby, E., G. Biberfeld, F. Chiodi, A. von Gegerfeldt, A. Nauclér, E. Parks, and R. Lerner. 1987. Discrimination between antibodies to HIV and to related retroviruses using site-directed serology. Nature 329:248-250[Medline]. |
| 27. |
Oldstone, M. B. A.,
A. Tishon,
H. Lewicki,
H. J. Dyson,
V. A. Feher,
N. Assa-Munt, and P. E. Wright.
1991.
Mapping the anatomy of the immunodominant domain of the human immunodeficiency virus gp41 transmembrane protein: peptide conformation analysis using monoclonal antibodies and proton nuclear magnetic resonance spectroscopy.
J. Virol.
65:1727-1734 |
| 28. | Pancino, G., L. Camoin, and P. Sonigo. 1995. Structural analysis of the principal immunodominant domain of the feline immunodeficiency virus transmembrane glycoprotein. J. Virol. 69:2110-2118[Abstract]. |
| 29. |
Pancino, G.,
C. Chappey,
W. Saurin, and P. Sonigo.
1993.
B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins.
J. Virol.
67:664-672 |
| 30. | Pancino, G., H. Ellerbrok, M. Sitbon, and P. Sonigo. 1994. Conserved framework of envelope glycoproteins among lentiviruses. Curr. Top. Microbiol. Immunol. 188:77-105[Medline]. |
| 31. | Pancino, G., T. Leste-Lasserre, M. Burgard, D. Costagliola, S. Ivanoff, S. Blanche, C. Rouzioux, and P. Sonigo. 1998. Apparent enhancement of perinatal transmission of human immunodeficiency virus type 1 by high maternal anti-gp160 antibody titer. J. Infect. Dis. 177:1737-1741[Medline]. |
| 32. | Pancino, G., and P. Sonigo. 1997. Retention of viral infectivity after extensive mutation of the highly conserved immunodominant domain of the feline immunodeficiency virus envelope. J. Virol. 71:4339-4346[Abstract]. |
| 33. | Pleskoff, O., N. Sol, B. Labrosse, and M. Alizon. 1997. Human immunodeficiency virus strains differ in their ability to infect CD4+ cells expressing the rat homolog of CXCR-4 (fusin). J. Virol. 71:3259-3262[Abstract]. |
| 34. |
Robinson, W. E., Jr.,
M. K. Gorny,
J.-Y. Xu,
W. M. Mitchell, and S. Zolla-Pazner.
1991.
Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.
J. Virol.
65:4169-4176 |
| 35. |
Robinson, W. E., Jr.,
T. Kawamura,
D. Lake,
Y. Masuho,
W. M. Mitchell, and E. M. Hersh.
1990.
Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein 41 enhance HIV-1 infection in vitro.
J. Virol.
64:5301-5305 |
| 36. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 37. |
Sattentau, Q. J., and J. P. Moore.
1991.
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.
J. Exp. Med.
174:407-415 |
| 38. |
Sattentau, Q. J., and J. P. Moore.
1995.
Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
J. Exp. Med.
182:185-196 |
| 39. | Sattentau, Q. J., S. Zolla-Pazner, and P. Poignard. 1995. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206:713-717[Medline]. |
| 40. | Schulz, T. F., B. A. Jameson, L. Lopalco, A. G. Siccardi, R. A. Weiss, and J. P. Moore. 1992. Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins? AIDS Res. Hum. Retroviruses 8:1571-1580[Medline]. |
| 41. | Schwartz, O., M. Alizon, J.-M. Heard, and O. Danos. 1994. Impairment of T cell receptor-dependent stimulation in CD4+ lymphocytes after contact with membrane-bound HIV-1 envelope glycoprotein. Virology 198:360-365[Medline]. |
| 42. | Shioda, T., J. A. Levy, and C. Cheng-Mayer. 1991. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp 120 gene. Nature 349:167-169[Medline]. |
| 43. |
Stamatatos, L., and C. Cheng-Mayer.
1993.
Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability.
J. Virol.
67:5635-5639 |
| 44. | Stamatatos, L., and C. Cheng-Mayer. 1995. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J. Virol. 69:6191-6198[Abstract]. |
| 45. |
Stein, B., and E. Englemann.
1990.
Intracellular processing of the gp160 HIV-1 envelope precursor.
J. Biol. Chem.
265:2640-2649 |
| 46. |
Syu, W.-J.,
W.-R. Lee,
B. Du,
Q.-C. Yu,
M. Essex, and T.-H. Lee.
1991.
Role of conserved gp41 cysteine residues in the processing of human immunodeficiency virus envelope precursor and viral infectivity.
J. Virol.
65:6349-6352 |
| 47. | Weissenhorn, W., A. Dessen, S. C. Harrison, J. J. Skehel, and D. C. Wiley. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430[Medline]. |
| 48. |
Westervelt, P.,
H. E. Gendelman, and L. Ratner.
1991.
Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.
Proc. Natl. Acad. Sci. USA
88:3097-3101 |
| 49. |
Willey, R. L.,
J. S. Bonifacino,
B. J. Potts,
M. A. Martin, and R. D. Klausner.
1988.
Biosynthesis, cleavage, and degradation of the human immunodeficiency virus type 1 envelope glycoprotein gp160.
Proc. Natl. Acad. Sci. USA
85:9580-9584 |
| 50. |
Willey, R. L.,
T. S. Theodore, and M. A. Martin.
1994.
Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope.
J. Virol.
68:4409-4419 |
| 51. | Wrin, T., T. P. Loh, J. C. Vennari, H. Schuitemaker, and J. H. Nunberg. 1995. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J. Virol. 69:39-48[Abstract]. |
| 52. |
Xu, J.-Y.,
M. K. Gorny,
T. Palker,
S. Karwowska, and S. Zolla-Pazner.
1991.
Epitope mapping of two immunodominant domains of gp41 transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.
J. Virol.
65:4832-4838 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»